Chimeric hepatocyte growth factor (HGF) ligand variants
AssigneeGenentech, Inc.
InventorPaul J. Godowski
Life of this patent
Estimating the term…
Abstract
The invention concerns a method for activating receptors selected from receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily. A conjugate comprising the direct fusion of at least two ligands capable of binding to the receptor(s) to be activated is contacted with the receptors, whereby the ligands bind their respective receptors inducing receptor oligomerization.
Claims5
A chimeric molecule comprising a dimer of two monomers each of said monomers being a fusion protein of a hepatocyte growth factor (HGF) ligand variant to an immunoglobulin constant domain sequence, wherein said dimer is formed by linking the immunoglobulin constant domain of the two monomers, wherein each monomer alone binds to the HGF receptor, but wherein at least one monomer alone does not activate the tyrosine kinase activity of the HGF receptor, and wherein the dimer binds and activates the tyrosine kinase activity of the HGF receptor.
A chimeric molecules wherein the chimeric molecule is selected from the group consisting of NK2-IgG;
- NK1-IgG;
- Y673S, V692S HGF-IgG;
- and R494E HGF-IgG.
Dependencies are inferred from the claim text.